The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma

Author(s):

Linyan Xu, Yuanyuan Qin, Mengdi Liu, Jun Jiao, Dongyun Tu, Meng Zhang, Dongmei Yan, Xuguang Song, Cai Sun, Feng Zhu, Xiangmin Wang, Wei Sang* and Kailin Xu*   Pages 1530 - 1540 ( 11 )

Abstract:

<P>Background: Extranodal natural killer/T cell lymphoma (ENKTL) is an aggressive malignant non- Hodgkin&#039;s lymphoma (NHL) with a poor prognosis. Therefore, novel therapeutic biomarkers and agents must be identified for the same. KAT5 inhibitor, NU 9056, is a small molecule that can inhibit cellular proliferation; however, its role in ENKTL has not been studied. <P> Objective: The present study investigated the effect of NU 9056 in ENKTL cells and explored the possible molecular mechanism for its antitumour effect. <P> Methods: The role of NU 9056 in ENKTL cells was investigated through the Cell Counting Kit-8 assay, flow cytometry, Western blot, and real-time quantitative polymerase chain reaction assay. <P> Results: NU 9056 inhibited ENKTL cell proliferation and induced G2/M phase arrest. NU 9056 also induced apoptosis by upregulating DR4, DR5, and caspase 8 expressions. Additionally, NU 9056 increased the expression of Bax, Bid, and cytochrome C and decreased the expression of Bcl-2, Mcl-1, and XIAP. Furthermore, NU 9056 activated endoplasmic reticulum (ER) stress and inhibited the JAK2/STAT3 signalling pathway. The p38 mitogen-activated protein kinase (MAPK) signalling pathway was also activated by NU 9056, and the ERK signalling pathway was suppressed in natural killer/T cell lymphoma cells. <P> Conclusion: NU 9056 inhibited cell proliferation, arrested cell cycle in the G2/M phase, and induced apoptosis through the stimulation of ER stress, thus inhibiting the JAK2/STAT3 signalling pathway and regulating MAPK pathways in ENKTL cells.</P>

Keywords:

NU 9056, ENKTL, KAT5, apoptosis, JAK2/STAT3, MAPK.

Affiliation:

Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, Department of Hematology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu, Blood Diseases Institute, Xuzhou Medical University, Xuzhou, Jiangsu

Graphical Abstract:

Read Full-Text article